AA
VIVO

AlphaMark Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

AlphaMark Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-193
Closed -$5K – 310
2013
Q3 		$5K Hold
193
– – ﹤0.01% 277
2013
Q2 		$4K Buy
+193
New +$4.16K ﹤0.01% 358

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

AlphaMark Advisors's VIVO Position: Q4 2013 in Review

AlphaMark Advisors sold out of Meridian Bioscience Inc (VIVO) in Q4 2013, closing a stake of 193 shares — an estimated $5K sold.

AlphaMark Advisors first reported a position in VIVO in Q2 2013 and held it in 2 quarters. The position peaked at $5K in Q3 2013. 170 funds tracked by Wall St. Rank hold VIVO as of Q4 2013.

  • AlphaMark Advisors reported no remaining Meridian Bioscience Inc position as of Q4 2013 after selling out during the quarter.
  • AlphaMark Advisors sold 193 Meridian Bioscience Inc shares in Q4 2013, an estimated $5K.
  • AlphaMark Advisors first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 2 quarters.
  • AlphaMark Advisors's Meridian Bioscience Inc position peaked at $5K in Q3 2013.
  • 170 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2013.

Based on AlphaMark Advisors's 13F filing for Q4 2013, filed 30 Jan 2014.